IRLAB Therapeutics AB (publ) (IRLAB-A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has a cash flow conversion efficiency ratio of -0.787x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-24.18 Million ≈ $-2.60 Million USD) by net assets (Skr30.72 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of IRLAB Therapeutics AB (publ) to measure how many days the company can operate on defensive assets alone.
IRLAB Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how IRLAB Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
IRLAB Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euro Manganese Inc
V:EMN
|
3.655x |
|
Baillie Gifford US Growth Trust PLC
LSE:USA
|
-0.004x |
|
Magna Terra Minerals Inc
V:MTT
|
-0.282x |
|
Magnum Mining and Exploration Ltd
AU:MGU
|
-0.164x |
|
Serica Energy PLC
LSE:SQZ
|
0.080x |
|
Alligator Bioscience AB
ST:ATORX
|
-3.791x |
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
0.027x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
Annual Cash Flow Conversion Efficiency for IRLAB Therapeutics AB (publ) (2014–2025)
The table below shows the annual cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see IRLAB-A company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr30.72 Million ≈ $3.31 Million |
Skr-55.22 Million ≈ $-5.94 Million |
-1.798x | +10.56% |
| 2024-12-31 | Skr32.63 Million ≈ $3.51 Million |
Skr-65.59 Million ≈ $-7.06 Million |
-2.010x | -41.14% |
| 2023-12-31 | Skr115.76 Million ≈ $12.46 Million |
Skr-164.85 Million ≈ $-17.74 Million |
-1.424x | -190.40% |
| 2022-12-31 | Skr290.83 Million ≈ $31.30 Million |
Skr-142.61 Million ≈ $-15.35 Million |
-0.490x | -252.28% |
| 2021-12-31 | Skr399.48 Million ≈ $42.99 Million |
Skr128.64 Million ≈ $13.84 Million |
0.322x | +225.57% |
| 2020-12-31 | Skr347.88 Million ≈ $37.44 Million |
Skr-89.21 Million ≈ $-9.60 Million |
-0.256x | +48.87% |
| 2019-12-31 | Skr181.83 Million ≈ $19.57 Million |
Skr-91.20 Million ≈ $-9.81 Million |
-0.502x | -50.55% |
| 2018-12-31 | Skr212.48 Million ≈ $22.87 Million |
Skr-70.79 Million ≈ $-7.62 Million |
-0.333x | +10.56% |
| 2017-12-31 | Skr155.00 Million ≈ $16.68 Million |
Skr-57.74 Million ≈ $-6.21 Million |
-0.373x | +5.19% |
| 2016-12-31 | Skr103.89 Million ≈ $11.18 Million |
Skr-40.82 Million ≈ $-4.39 Million |
-0.393x | -30.74% |
| 2015-12-31 | Skr92.03 Million ≈ $9.90 Million |
Skr-27.66 Million ≈ $-2.98 Million |
-0.301x | -141.45% |
| 2014-12-31 | Skr88.57 Million ≈ $9.53 Million |
Skr-11.02 Million ≈ $-1.19 Million |
-0.124x | -- |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more